secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2026-08-11T20:06:20+00:00
Accession:  0001493152-26-037124
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata to launch Tome Foundational Treatment on Aug 25, 2026; cash $4.4M
-------------------------------------------------------------------------

- Tome Foundational Treatment launch expected Aug 25, 2026; manufacturing and packaging complete.
- Cash and equivalents $4.4M at June 30, 2026 vs $7.5M at Dec 31, 2025; sufficient into Q4 2026.
- Q2 2026 R&D expenses $0.2M (down from $0.6M); SG&A $2.8M (up from $1.2M) on legal, marketing, compensation.
- Second DTC product, an OTC acne treatment, planned after Foundational Treatment launch.
- Company attended Be+Well Beauty and Wellness Show in June; began Tome social media campaign.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/0001493152-26-037124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer